IRIDEX (NASDAQ:IRIX) Major Shareholder Purchases $48,859.24 in Stock

Posted by Francis Steltz on Oct 10th, 2026

IRIDEX Corporation (NASDAQ:IRIX – Get Free Report) major shareholder Shih-Yao David Lin purchased 33,013 shares of IRIDEX stock in a transaction that occurred on Tuesday, January 27th. The shares were bought at an average price of $1.48 per share, for a total transaction of $48,859.24. Following the transaction, the insider owned 1,034,312 shares in the company, valued at $1,530,781.76. This represents a 3.30% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Major shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

IRIDEX Trading Down 0.9%

IRIX opened at $0.89 on Friday. The stock has a market capitalization of $15.64 million, a PE ratio of -4.45 and a beta of 0.67. IRIDEX Corporation has a 1-year low of $0.61 and a 1-year high of $1.65. The firm has a 50-day moving average price of $0.73 and a two-hundred day moving average price of $0.95.

IRIDEX (NASDAQ:IRIX – Get Free Report) last announced its earnings results on Tuesday, August 18th. The medical equipment provider reported ($0.07) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.06). The business had revenue of $12.57 million for the quarter, compared to the consensus estimate of $13.59 million. On average, research analysts predict that IRIDEX Corporation will post -0.12 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised IRIDEX from a “sell (e+)” rating to a “sell (d-)” rating in a report on Friday, October 2nd. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $3.00.

View Our Latest Report on IRIX

Institutional Investors Weigh In On IRIDEX

A number of institutional investors and hedge funds have recently modified their holdings of IRIX. Perkins Capital Management Inc. boosted its stake in IRIDEX by 33.9% in the first quarter. Perkins Capital Management Inc. now owns 55,300 shares of the medical equipment provider’s stock valued at $56,000 after acquiring an additional 14,000 shares during the last quarter. Thompson Davis & CO. Inc. raised its position in shares of IRIDEX by 66.5% during the 1st quarter. Thompson Davis & CO. Inc. now owns 47,444 shares of the medical equipment provider’s stock valued at $48,000 after acquiring an additional 18,944 shares during the last quarter. Renaissance Technologies LLC raised its position in shares of IRIDEX by 6.7% during the 1st quarter. Renaissance Technologies LLC now owns 396,627 shares of the medical equipment provider’s stock valued at $401,000 after acquiring an additional 25,067 shares during the last quarter. Bank of New York Mellon Corp acquired a new position in shares of IRIDEX in the 2nd quarter valued at $29,000. Finally, Diversify Wealth Management LLC acquired a new position in shares of IRIDEX in the 1st quarter valued at $35,000. 20.10% of the stock is owned by institutional investors.

IRIDEX Company Profile

(Get Free Report)

IRIDEX Corporation (NASDAQ: IRIX) develops and sells ophthalmic laser systems and related delivery devices used in the treatment of eye diseases. Its products are designed primarily for ophthalmologists treating glaucoma and retinal disorders, including diabetic retinopathy and other conditions affecting the retina.

The company’s portfolio includes laser systems such as the Cyclo G6 glaucoma laser platform and the IQ series of retinal photocoagulation lasers. IRIDEX also offers specialized probes and other delivery devices, including MicroPulse and transscleral cyclophotocoagulation technologies, which are intended to provide targeted treatment while limiting exposure to surrounding tissue.

Founded in 1989 and headquartered in Mountain View, California, IRIDEX serves eye-care professionals through a combination of direct sales and distributor relationships in the United States and international markets.